GAMMA Investing LLC Acquires 110 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

GAMMA Investing LLC grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 17.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 726 shares of the biopharmaceutical company’s stock after purchasing an additional 110 shares during the quarter. GAMMA Investing LLC’s holdings in Alnylam Pharmaceuticals were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. SVB Wealth LLC bought a new position in Alnylam Pharmaceuticals in the 1st quarter worth $27,000. Whipplewood Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares during the period. Washington Trust Advisors Inc. raised its holdings in Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 61 shares during the period. Finally, Larson Financial Group LLC raised its holdings in Alnylam Pharmaceuticals by 77.7% in the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 87 shares during the period. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ALNY. HC Wainwright reiterated a “buy” rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, September 2nd. Chardan Capital lifted their target price on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Needham & Company LLC raised their price target on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Finally, Oppenheimer upgraded shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target on the stock in a research report on Monday, August 4th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $439.58.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 11,250 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $450.00, for a total value of $5,062,500.00. Following the transaction, the director directly owned 16,804 shares in the company, valued at $7,561,800. The trade was a 40.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Pushkal Garg sold 1,455 shares of the business’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total transaction of $666,986.55. Following the completion of the transaction, the executive vice president owned 20,221 shares in the company, valued at approximately $9,269,508.61. This trade represents a 6.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 75,594 shares of company stock worth $33,968,256 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of Alnylam Pharmaceuticals stock opened at $446.40 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm’s 50-day simple moving average is $428.51 and its 200-day simple moving average is $332.08. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $484.21. The firm has a market cap of $58.51 billion, a P/E ratio of -180.73 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same period in the previous year, the business earned ($0.13) EPS. The firm’s revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.